LEIDEN JEFFREY M 4

Accession 0000875320-25-000242

CIK 0000875320other

View on SEC.gov Company Profile

Filed

Dec 4, 7:00 PM ET

Accepted

Dec 5, 4:10 PM ET

Size

30.6 KB

Accession

0000875320-25-000242

Insider Transaction Report

Form 4

Period: 2025-12-03

VERTEX PHARMACEUTICALS INC / MAVRTX

LEIDEN JEFFREY M

Director

Transactions

Exercise/Conversion
Common Stock
2025-12-03$86.52/sh+63,781$5,518,332→ 87,807 total
Sale
Common Stock
2025-12-03$440.40/sh−4,469$1,968,148→ 83,338 total
Sale
Common Stock
2025-12-03$441.26/sh−1,320$582,463→ 82,018 total
Sale
Common Stock
2025-12-03$443.21/sh−2,469$1,094,285→ 79,549 total
Sale
Common Stock
2025-12-03$444.36/sh−4,352$1,933,855→ 75,197 total
Sale
Common Stock
2025-12-03$445.56/sh−7,899$3,519,478→ 67,298 total
Sale
Common Stock
2025-12-03$447.05/sh−1,152$515,002→ 66,146 total
Sale
Common Stock
2025-12-03$448.78/sh−2,320$1,041,170→ 63,826 total
Sale
Common Stock
2025-12-03$449.84/sh−5,880$2,645,059→ 57,946 total
Sale
Common Stock
2025-12-03$451.20/sh−5,809$2,621,021→ 52,137 total
Sale
Common Stock
2025-12-03$452.20/sh−15,681$7,090,948→ 36,456 total
Sale
Common Stock
2025-12-03$453.34/sh−10,360$4,696,602→ 26,096 total
Sale
Common Stock
2025-12-03$455.22/sh−2,070$942,305→ 24,026 total
Exercise/Conversion
Common Stock
2025-12-04$91.05/sh+1$91→ 24,027 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-12-03−63,781→ 0 total
Exercise: $86.52Exp: 2027-02-02→ Common Stock (63,781 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-12-04−1→ 0 total
Exercise: $91.05Exp: 2026-02-01→ Common Stock (1 underlying)

Holdings

Common Stock
(indirect: By 401(k))
440

Footnotes (15)

[F1]Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.
[F10]Open market sales reported on this line occurred at a weighted average price of $449.84 (range $449.22 to $450.18).
[F11]Open market sales reported on this line occurred at a weighted average price of $451.20 (range $450.71 to $451.70).
[F12]Open market sales reported on this line occurred at a weighted average price of $452.20 (range $451.73 to $452.69).
[F13]Open market sales reported on this line occurred at a weighted average price of $453.34 (range $452.91 to $453.70).
[F14]Open market sales reported on this line occurred at a weighted average price of $455.22 (range $454.88 to $455.66).
[F15]Fully vested.
[F2]Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
[F3]Open market sales reported on this line occurred at a weighted average price of $440.40 (range $440.04 to $441.00).
[F4]Open market sales reported on this line occurred at a weighted average price of $441.26 (range $441.14 to $442.00).
[F5]Open market sales reported on this line occurred at a weighted average price of $443.21 (range $442.94 to $443.93).
[F6]Open market sales reported on this line occurred at a weighted average price of $444.36 (range $444.00 to $444.94).
[F7]Open market sales reported on this line occurred at a weighted average price of $445.56 (range $445.00 to $445.82).
[F8]Open market sales reported on this line occurred at a weighted average price of $447.05 (range $447.00 to $447.23).
[F9]Open market sales reported on this line occurred at a weighted average price of $448.78 (range $448.18 to $449.12).

Documents

1 file

4
wk-form4_1764969035.xmlPrimary
FORM 4

Issuer

VERTEX PHARMACEUTICALS INC / MA

CIK 0000875320

→

Entity typeother

Related Parties

filerCIK 0001242825

Filing Metadata

Form type: 4
Filed: Dec 4, 7:00 PM ET
Accepted: Dec 5, 4:10 PM ET
Size: 30.6 KB

View on SEC.gov